Abbreviated New Drug Application (ANDA)
An ANDA is an abbreviated version of New Drug Application (NDA). It is allowed for duplicates of drug products that were first approved before October 10, 1962 and for certain other drugs which are described in the CFR. Its main use is to obtain FDA approval for generic drugs.
More information about Abbreviated New Drug Application (ANDA)
Drugs,andas,drug applications,approvals,route of administration,studies,amendments,dosage forms,generic drug product,patent,guidance,active ingredient,quality,form,method,generic drugs,drug products.
Bioequivalence studies,ingredient,risks,active moiety,Therapeutic Equivalence,regulatory requirements,brand-name drug,patent term extension,period,draft guidance.
U.S.C.,Inactive ingredients,Hatch-Waxman Amendment,systems,United States,public disclosure,generic product,abbreviated.
Application,Food and Drug Administration,patent owner,submission of patent information,claim of patent infringement,applicant for approval,requirements for approval,notice,notice requirements,notice.
With respect,180-day exclusivity period,45-day period,guidance documents,impurity,technical amendment,Health and Human Services,Risk evaluation,Orange Book,complete.
Application,Requirements for submission,Civil action,drug product manufacturer,Center for Drug Evaluation,drug product intermediate,generic drug activities,innovator drug,patent certification requirements,filing of patent information.
Patent listing disputes,action for patent infringement,patent infringement litigation,bundle of patent rights,timing of approval,stays of approval,notice of paragraph,retest period,postapproval study,transportation study,Q1A guidance document,U.S.C. 379j–41,U.S.C. 379j–41 et seq,U.S.C. 379j–41 et seq.,therapeutic ingredient,Unspecified impurities,potential impurities,mutagenic impurities,ANDA holder,ANDA with deference,Quality Module,Quality of Aqueous Solutions,Form FDA,Health Canada,Health Canada’s,patented method,submission of method,active postmarket risk identification,Biopharmaceutics Classification System,Adverse Event Reporting System.